Dihexa
- Category
- Brain & Cognition
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
What it is
A synthetic, orally active peptide marketed for memory and cognition, said to amplify HGF signaling and spur new synapse formation. The case rests entirely on rodent studies, with only speculative results in an Alzheimer's mouse model and no human safety data. Its core mechanism, HGF/c-Met, is a known cancer-promoting pathway, and the 2014 paper establishing it was retracted in 2025. It is an unregulated research chemical, not an approved drug in the US.
Read Full recordStudied uses & evidence
Studied uses(6)
Potent synaptogenesis promotion
LowCultured rat neurons grew more dendritic spines at picomolar doses in one 2013 study.
Rescue of scopolamine-induced cognitive deficits
LowOral dosing reversed a chemically induced memory deficit in rats, one lab, no human data.
Cognitive restoration in Alzheimer's mouse model
SpeculativeA 2021 APP/PS1 mouse study reported improved spatial learning; no human cognitive benefit is established.
Evidence limits
- Evidence Level
- Preclinical
All published evidence for dihexa itself comes from in vitro cell culture studies and rodent models. No human clinical trials of dihexa have been conducted or published. The pro-drug fosgonimeton has undergone Phase 2/3 human trials for Alzheimer's disease (LIFT-AD study), which did not meet primary endpoints but showed directional biomarker improvements. The foundational 2014 mechanism paper was retracted in April 2025, adding uncertainty to some claims.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighAmplifies HGF/c-Met signaling, which is a known oncogenic pathway in many cancers.
General cautions
Pregnancy
AbsoluteHGF pathway is critical for embryonic development. Modulation could be teratogenic.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
HGF/c-Met signaling is a well-established oncogenic pathway
HighDose-dependent hepatotoxicity reported in rodents
TheoreticalAberrant dendritic branching at high doses in animals
TheoreticalNo peer-reviewed human safety trials exist; all safety data from rodents
HighThe 2014 Benoist et al. paper establishing the HGF/c-Met mechanism was retracted in 2025
HighUnregulated products sold online; quality varies
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.